Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-875 · 7 trials · 3 indications
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 relative to baseline.
| Arm | Type | Description |
|---|---|---|
| TAK-875 25 mg | EXPERIMENTAL | - |
| TAK-875 50 mg | EXPERIMENTAL | - |
| Glimepiride | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Placebo QD | PLACEBO_COMPARATOR | - |
| TAK-875 25 mg QD | EXPERIMENTAL | - |
| TAK-875 50 mg QD | EXPERIMENTAL | - |
| Sitagliptin 100 mg QD | EXPERIMENTAL | - |
| TAK-875 25 mg QD + Sitagliptin 100 mg QD | EXPERIMENTAL | - |
| TAK-875 50 mg QD + Sitagliptin 100 mg QD | EXPERIMENTAL | - |
| TAK-875 6.25 mg QD | EXPERIMENTAL | - |
| TAK-875 100 mg QD | EXPERIMENTAL | - |
| TAK-875 200 mg QD | EXPERIMENTAL | - |
| Glimepiride 2 mg or 4mg QD | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TAK-875 | DRUG | - |
| Glimepiride | DRUG | - |
| Placebo | DRUG | - |
| Sitagliptin | DRUG | Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks. |
| TAK-875 and Sitagliptin | DRUG | TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks. |
Inclusion Criteria: * The participant is an outpatient. * The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures. Exclusion Criteria: * The participant has any serious cardiac disease, serious cerebro...
TAK-875 is an investigational small molecule being developed for type 2 diabetes mellitus. It has been studied in clinical trials for its effects on blood sugar control, including in combination with sitagliptin, and in long-term studies for diabetes management.
TAK-875 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company has sponsored clinical trials of the drug in patients with type 2 diabetes.
TAK-875 has completed Phase 3 clinical trials. It is an investigational drug and has not been approved by regulatory authorities. Its development program includes completed Phase 1, Phase 2, and Phase 3 studies.
TAK-875 has been studied in several completed trials. NCT00949091 examined its pharmacokinetics and pharmacodynamics in type 2 diabetes. NCT01007097 and NCT01414920 assessed efficacy and safety, including with sitagliptin. NCT01433406 was a long-term study in diabetes.
TAK-875 is a small molecule developed for type 2 diabetes. Its specific molecular target has not been disclosed in the available clinical trial information. The drug has been evaluated for its ability to improve glycemic control in diabetic patients.
TAK-875 is the only name provided for this investigational drug. No alternative names have been identified in the clinical trial records. It is distinct from other diabetes medications studied in combination with it, such as sitagliptin.